Citations

Clear

9383 citation(s) found for "Thomas, PS".

Integrated high‐resolution copy number and histomolecular analysis of diffuse hemispheric glioma, H3 G34 ‐mutant reveals universal TP53 abnormalities
Trejo-Lopez, Jorge, Mendoza, Cinthya Zepeda, Kollmeyer, T. M., Decker, P. A., Hardcastle, Jayson, Smoley, Stephanie A., Isaacson, Matthew , Gandham, Mallika , Dasari, Surendra, Raghunathan, Aditya, Giannini, Caterina, Zheng, Gang, Wagner, Aaron S., Lopes, M Beatriz, Fung, K Samuel, Peterson, JoElle, Rivera, Andreana L., Rossi, Christopher , Walsh, Meggen, Abdullaev, Zied , Aldape, Kenneth, Quezado, Martha, Cimino, Patrick Joseph, Jenkins, Robert B, Trejo‐Lopez, Jorge , Trejo-Lopez, Jorge A , Zepeda-Mendoza, Cinthya J , Kollmeyer, Thomas M. , Pazdernik, Vanessa M, Praska, Corinne E, Smoley, Stephanie , Lopes, M Beatriz , Ida, Cristiane M , Zepeda‐Mendoza, Cinthya , Drucker, Kristen , Pazdernik, Vanessa , Praska, Corinne , Dasari, Surendra, Raghunathan, Aditya , Giannini, Caterina , Lopes, M. Beatriz S. , Quezado, Martha , Pratt, Drew , Cimino, Patrick J. , Ida, Cristiane M.

Mayo Clinic

Brain Pathology | February 6, 2026 | Volume: 36 | Issue: 4 | Pages: No page available

10.1111/bpa.70076 | PMID 41649072 Get It

Abstract Diffuse hemispheric glioma, H3 G34‐mutant (DHG‐H3 G34) has been primarily molecularly characterized by methylation profiling and sequencing studies. We describe an integrated histomolecular evaluation including high‐resolution copy number profiling of a series of 60 DHG‐H3 G34 to further our understanding of the spectrum of genetic changes associated with this tumor type. Cases were clinically tested using an 187‐gene mutation and fusion targeted neuro‐oncology next‐generation sequencing panel ( n = 60) and Oncoscan chromosomal microarray ( n = 26) by a single laboratory (2018–2022). A subset of cases had immunohistochemical results for OLIG2 ( n = 42), p53 ( n = 48), and ATRX ( n = 46), and methylation array data ( n = 8). Median age at testing was 21 years (range, 12–50). No significant difference was noted in clinical, histopathological, and mutational profile between pediatric and adult patients. H3‐3A G34 mutations included G34R ( n = 56; 94%), G34V ( n = 3), and a non‐canonical G34E ( n = 1). Concurrent mutations most often involved TP53 ( n = 55; 92%), ATRX ( n = 50; 83%), and PDGFRA ( n = 34; 57%). A reportedly primary tumor was confirmed to be hypermutant and had a PMS2 mutation. A single case also showed an FGFR3::FAM184B fusion. All cases with available chromosomal microarray data had unbalanced genomes, which were often complex (14/26; 54%). The most frequent recurrent copy number abnormalities were losses involving 3q, 4q, 10q, 13q, and 18q, and 17p copy‐neutral loss of heterozygosity (cnLOH) encompassing TP53 . This copy number profile was reminiscent of that seen in Grade 4 IDH‐mutant astrocytomas. Collectively, a TP53 abnormality at copy number (12/26, all cnLOH), sequence (55/60) and protein expression (46/48) level was detected in all 60 cases. In conclusion, integrated high‐resolution copy number and histomolecular analysis expanded the spectrum of genetic changes associated with DHG‐H3 G34, including the presence of universal TP53 abnormalities with frequent cnLOH—a copy number abnormality that has been largely unrecognized—for this new 2021 World Health Organization central nervous system tumor type.
Natural History of Patients With Histologically Proven Acute Eosinophilic Myocarditis
Ammirati, Enrico, Palazzini, Matteo , Lehtonen, Jukka , Potena, Luciano , Mäyränpää, Mikko I. , Rågback, Johanna, Uribarri, Aitor , Thiele, H, Vidal‐Burdeus, María , Freund, Anne, Gustafsson, F., Tschöpe, C., Elsanhoury, Ahmed , Ihle, Joshua , Rudi, Wolf‐Stephan , Grabmaier, Ulrich , Merlo, Marco, Weislova, Ivana, Jellinghaus, Stefanie, Linke, A, Baldovini, Chiara , Adorisio, R, Kuchyňka, Petr, Palecek, T, Krejčí, Jan, Poloczková, Hana , Caterino, Anna Laura, Lovell, Jana , Macomb, Elaine P., Shih, Jeffrey, Hong, Kimberly N. , Ruschitzka, Frank, Cavallini, Claudio, Riccini, Clara, Kamal, Mohamed, Groh, Matthieu, Garascia, Andrea , Lala, Anuradha, Shimokawa, Hiroaki, Sionis, A, Schmidt, Matthieu, Grosu, Aurelia, Bollano, Entela , Turco, Annalisa , Crespo-Leiro, M., Couto-Mallón, David, Cannata, Antonio, Narducci, M L, Cicchitti, Vincenzo , Ianni, Umberto , L, De Luca, Frea, Simone, Schroeder, J. W., Arias, Aníbal , Emdin, Michele, Corda, Marco , Pasqualucci, Daniele , Greulich, Simon , Gawaz, M, Manuylova, Tatiana, Martinez-Selles, M, Pérez, Francisco José Hernández, Centellas, Alba Martín , Trankle, Cory R. , Halushka, Marc K., Abbate, Antonio, Basso, Cristina, Sinagra, Gianfranco, Veronese, Giacomo , Camici, PG, Adler, Eric D., Cooper, Leslie T., Gustafsson, Finn , Tschöpe, Carsten , Thiele, Hölger , Ammirati, Enrico , Potena, Luciano , Ammirati, Enrico , Foà, Alberto , Uribarri, Aitor , Thiele, Holger , Vidal-Burdeus, María , Freund, Anne , Gustafsson, Finn , Tschöpe, Carsten , Elsanhoury, Ahmed , Ihle, Joshua , Grabmaier, Ulrich , Merlo, Marco , Melenovský, Vojtěch , Weislova, Ivana , Linke, Axel , Baldovini, Chiara , Kuchynka, Petr , Krejčí, Jan , Gilotra, Nisha A , Hong, Kimberly , Rossi, Valentina A , Ruschitzka, Frank T. , Kamal, Mohamed , Huang, Florent , Groh, Matthieu , Gentile, Piero , Garascia, Andrea , Shimokawa, Hiroaki , Vandenbriele, Christophe , Sionis, Alessandro , Schmidt, Matthieu , Bollano, Entela , Crespo-Leiro, Maria Generosa , Cannatà, Antonio , Bromage, Daniel I , Narducci, Maria Lucia , Cicchitti, Vincenzo , Ianni, Umberto , De Luca, Leonardo , Mistrulli, Raffaella , Frea, Simone , Raineri, Claudia , Schroeder, Jan W , Arias, Anibal Martin , Emdin, Michele , Greulich, Simon , Gawaz, Meinrad , Martínez-Sellés, Manuel , Hernández Pérez, Francisco José , Dominguez, Fernando , D'Alessandris, Nicoletta , Trankle, Cory , Halushka, Marc K , Moroni, Francesco , Abbate, Antonio , Basso, Cristina , Sinagra, Gianfranco , Veronese, Giacomo , Camici, Paolo G , Adler, Eric D , Bernasconi, Davide P , Klingel, Karin , Cooper, Leslie T , Foà, Alberto , Vidal-Burdeus, María , Merlo, M, Melenovský, Vojtěch , Adorisio, Rachele , Paleček, Tomáš , Krejčí, Jan , Cavallini, Claudio , Riccini, Clara, Gentile, Piero , Lala, Anuradha , Shimokawa, Hiroaki , Vandenbriele, Christophe , Couto‐Mallón, David , Luca, Leonardo De , Frea, Simone , Corda, Marco , Domínguez, Fernándo , Gaillet, Antoine , Halushka, Marc K. , Abbate, Antonio , Basso, Cristina , Cooper, Leslie T.

Mayo Clinic

Circulation | February 6, 2026 | Volume: 153 | Issue: 9 | Pages: 634-652

10.1161/circulationaha.125.074797 | PMID 41645905 Get It

BACKGROUND: No large registries of patients with acute eosinophilic myocarditis (EM) are available. However, EM is perceived as a cardiac disease with high mortality, affecting mainly young and middle-aged adults according to small series and case reports. Awareness of the clinical presentation, associated systemic conditions, treatments, and outcomes of this uncommon condition is an unmet need. METHODS: In this international, multicenter, retrospective cohort study, 53 centers screened 193 patients with histologically proven acute EM between 1992 and 2023. After the exclusion of patients with insufficient data (n=10), symptoms lasting >30 days (n=19), or histological diagnosis not confirmed after review (n=8), 156 patients were included. RESULTS: Median age at presentation was 48 years (first to third quartile, 34–59 years) with male predominance (67.3%), and only 2 were pediatric cases (≤16 years of age; 1.3%). The main signs and symptoms at presentation were dyspnea (75.6%), fever (61.3%), and chest pain (53.2%). Unexpectedly, peripheral eosinophilia was reported in only 57.4% of cases, with a median cell count of 630 eosinophils/μL. The median left ventricular ejection fraction at presentation was 32% (first to third quartile, 25%–48%). The disorders most frequently associated with EM were eosinophilic granulomatosis with polyangiitis (22.4% of cases) and hypersensitivity forms (14.1%). Idiopathic/undefined forms accounted for 44.9% of cases, and miscellaneous causes accounted for 18.6%. In-hospital death or need for heart transplantation (HTx) occurred in 23 patients (14.7%; 22 deaths and 1 HTx), despite 43.6% being treated with temporary mechanical circulatory support and 92.9% being treated with immunosuppressive agents. Estimated rates of death or HTx at 1 and 3 years were 19.0% and 23.8%. Increased age, decreased left ventricular ejection fraction on admission, and no immunosuppressive therapy during hospitalization were independent predictors of death or HTx. A nonsignificant higher occurrence of deaths or HTx was observed in the hypersensitivity form (46.1%) compared with the eosinophilic granulomatosis with polyangiitis–associated form (13.1%) at 3 years ( P =0.15). CONCLUSIONS: Acute EM can often present without peripheral eosinophilia, and rates of in-hospital and midterm mortality or HTx are high. Endomyocardial biopsy is required to reach the final diagnosis of EM because relying on peripheral eosinophilia can lead to missing diagnosis. In-hospital immunosuppression is associated with HTx-free survival, although tailored immunosuppressive therapies are needed to improve outcomes. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06447935.
Genome and Transcriptome-Wide Analyses Identify Multiple Candidate Genes and a Significant Polygenic Contribution in Bicuspid Aortic Valve
Thériault, Sébastien , Holdcraft, Jacob A., Sharipova, Dinara , Dębiec, Radosław , Peloso, Gina M., Al‐Kassou, Baravan , Swan, Elena Ashikhmina , Ballotta, Andrea, Björck, Hanna M. , Braund, Peter S. , Corriveau, François, Dagenais, François, Francke, Michael, Gorbatov, Svetlana, Guo, Dongchuan, Habchi, Karam M, Scouarnec, Solena Le , Lichtner, Peter , Nguyen, Thy B., Norris, R., Pibarot, P, Simonet, Floriane, Tm, Sundt, Tessler, Idit , Willer, Cristen J., Wittmann, Susanne, Yang, Bo, Berezovets, Igor, Doppler, S. , Dreßen, Martina, Knoll, Katharina, Puehler, T., Schunkert, H, Bissell, Malenka M. , Bolger, Aidan, Brion, M, Citro, Rodolfo, Deeb, G. Michael, Corte, Alessandro Della, Dina, C., Eriksson, Per, Evangelista, Arturo , Franco-Cereceda, Anders, Gilon, Dan, Hetherington, Simon, Huggins, G S, Krane, Markus , Tourneau, Thierry Le, Limongelli, Giuseppe, Mathieu, P., Messika-Zeitoun, David, Michelena, Hector I., Milewicz, Dianna, Murdock, David R. , Nickenig, G., Nistri, Stefano, Nöthen, M, Samani, Nilesh J. , Schott, J., Webb, Tom R., Abdelilah-Seyfried, Salim, Schumacher, Johannes, Trenkwalder, Teresa , Body, Simon C. , Dina, Christian , Brión, Marı́a , Peloso, Gina M. , Webb, Tom R. , Faucherre, Adèle , Debiec, Radoslaw M , Peloso, Gina M , Al-Kassou, Baravan , Aranki, Sary , Ashikhmina Swan, Elena , Björck, Hanna M , Boureau, Anne Sophie , Braund, Peter S , Folkersen, Lasse , Guo, Dongchuan , Heydarpour, Mahyar , Isselbacher, Eric M , Jopling, Chris , Laporte, Fabien , Le Scouarnec, Solena , Li, Zhonglin , Lichtner, Peter , Maj, Carlo , Manikpurage, Hasanga D , Nguyen, Thy B , Norris, Russell A , Pibarot, Phillippe , Sarubbi, Berardo , Simonet, Floriane , Sundt, Thoralf , Surakka, Ida , Tessler, Idit , Yang, Bo , Doppler, Stefanie A , Dreßen, Martina , Knoll, Katharina , Puehler, Thomas , Schunkert, Heribert , Bissell, Malenka M , Bossé, Yohan , Bossone, Eduardo , Brion, María , Citro, Rodolfo , de Vincentiis, Carlo , Deeb, G Michael , Della Corte, Alessandro , Dina, Christian , Durst, Ronen , Ensminger, Stephan , Eriksson, Per , Evangelista, Arturo , Franco-Cereceda, Anders , Gilon, Dan , Giusti, Betti , Hetherington, Simon L , Huggins, Gordon S , Le Tourneau, Thierry , Limongelli, Giuseppe , Mathieu, Patrick , Messika-Zeitoun, David , Michelena, Hector I , Milewicz, Dianna M , Muehlschlegel, Jochen D , Murdock, David R , Nickenig, Georg , Nistri, Stefano , Nöthen, Markus M , Prakash, Siddharth K , Samani, Nilesh J , Jacques Schott, Jean , Webb, Tom R , Zaffran, Stéphane , Eagle, Kim , Body, Simon C , Holdcraft, Jacob A., Bellino, Michele , Dagenais, François, Forte, Amalia , Frigiola, Alessandro , Guo, Dongchuan , Isselbacher, Eric M. , Nelson, Christopher P. , Ong, Chin Siang , Roychowdhury, Tanmoy , Surakka, Ida , Willer, Cristen J , Aviérinos, Jean-François , Bolger, Aidan P. , Bossé, Yohan , Bossone, Eduardo , Citro, Rodolfo , Deeb, G. Michael , Corte, Alessandro Della , Gilon, Dan, Huggins, Gordon S. , Tourneau, Thierry Le , Mathieu, Patrick , Messika–Zeitoun, David , Nistri, Stefano , Nöthen, Markus M. , Pluchinotta, Francesca Romana , Prakash, Siddharth K. , Schott, Jean‐Jacques , Zaffran, Stéphane , Abdelilah‐Seyfried, Salim , Eagle, Kim A. , Schumacher, Johannes

Mayo Clinic

Circulation | February 6, 2026 | Volume: 153 | Issue: 14 | Pages: 1060-1076

10.1161/circulationaha.125.074752 | PMID 41645906 Get It

BACKGROUND: Bicuspid aortic valve (BAV) is a frequent congenital heart defect with a high heritability. Despite this, only a limited number of genes have been associated with the disease, and the molecular mechanisms remain unexplained in most cases. This study aimed to further understand the genetic architecture of BAV. METHODS: A genome-wide association study meta-analysis including 9631 cases among 65 677 participants was performed. Genes were prioritized using transcriptomic analyses based on RNA sequencing in relevant tissues, including human fetal and adult aortic valves. The impact of the knockdown or knockout of 4 candidate genes on cardiac development was verified in zebrafish. A polygenic risk score was developed, its association with BAV was evaluated in an independent cohort, and its association with a wide range of phenotypes (n=976) was evaluated in UK Biobank (n=355 618 individuals). RESULTS: Thirty-six genomic loci were identified, including 32 that were not described previously. Among the prioritized genes, KANK2 and ERBB4 were identified as potentially causal through transcriptomic analyses, colocalization, and Mendelian randomization based on gene expression in human aortic valves (n=484), whereas PRDM6 and STRN were prioritized using similar analyses from aortic (n=326) and left ventricular tissues (n=326), respectively. Targeting 4 candidate genes ( WNT4 , LEF1 , STRN , and KANK2 ) in zebrafish led to disruption in cardiac development. A polygenic risk score was associated with an odds ratio of 2.07 (95% CI, 1.90–2.25; P =5.43×10 -62 ) per SD for BAV and significantly associated with thoracic aortic aneurysm and atrial fibrillation in UK Biobank. CONCLUSIONS: This study supports a significant polygenic contribution to BAV, where the combination of multiple common variants in genes involved in heart morphogenesis disrupts aortic valve development.
Heart rate vigor score: an analysis of supramaximal heart rate mortality outcomes based on heart rate vigor assessment
Patel, P S, Newman, D B, Allison, T G, Newman, Darrell B. , Allison, Thomas G.

Mayo Clinic

European Heart Journal | February 5, 2026 | Volume: 46 | Issue: Supplement_1 | Pages: No page available

10.1093/eurheartj/ehaf784.3906 Get It

Abstract Background Inability to reach age-predicted peak heart rate (APPHR) of >85%, or submaximal heart rates, on treadmill exercise stress testing (TMET) is associated with increased mortality risk [1]. Evidence is limited on mortality outcomes with heart rates greater than APPHR, or ‘supramaximal’ heart rates, especially when using heart rate metrics alone. Purpose Use of a comprehensive, compositive assessment of heart rate, termed ‘vigor’, to determine mortality outcomes has yet to be explored, especially for those with supramaximal heart rates. We sought to investigate this relationship. Methods We queried our stress database from 1993-2010 for patients >30 years old without cardiovascular disease and not on antichronotropic therapy. Clinical and mortality outcomes were retrieved from patient records. Patients were stratified into groups based on APPHR as achieved on TMET: <75%, 75-84%, 85-94%, 95-104%, ≥105% of APPHR. For our study, heart rate ‘vigor’ served as a composite assessment of cardiovascular fitness based solely on heart rate. This was derived from resting heart rate, heart rate recovery, and achieved percentage of APPHR. A higher Heart Rate Vigor Score (HRViS) for this study was, by definition, indicative of better cardiac responsiveness and recovery following exertion. Patients were stratified based on their achieved HRViS. Scores were determined as follows: All patients were initially assigned 3 points. 1 point was subtracted for each of the following parameters met: resting heart rate >90 beats per minute (BPM), heart rate recovery <13 BPM, or submaximal heart rates of APPHR <85%. Patients that remained at HRViS 3 and achieved supramaximal heart rates (≥105% APPHR) were assigned an additional point, amounting to HRViS 4. HRViS stratifications are detailed in Table 1. Mortality rates were calculated for all HRViS stratifications, with adjustment for FAC and known confounders. HRViS 3 was used as the referent. Results 18,961 total patients were included. 88 patients were classified with HRViS of 0; 1,763 as HRViS 1; 5,409 as HRViS 2; 9,902 as HRViS 3; and 1,799 as HRViS 4. Those with lower HRViS scores had more comorbid conditions (Table 1). 2,144 patients achieved submaximal APPHR (<85%) on TMET, and 2,917 achieved supramaximal APPHR (≥105%). HRViS 0, 1, and 2 had higher mortality risks compared to referent HRViS 3: 0 [3.76 (2.34-6.04), p<0.0001]; 1 [1.80 (1.53-2.12), p<0.0001]; 2 [1.29 (1.12-1.48), p=0.0004]. HRViS 4 had a non-statistically significant trends towards lower mortality risk compared to 3: 0.85 (0.66-1.08), p=0.1768. Conclusions HRViS 4 had a non-statistical trend towards lower mortality risk. Our findings do not support concern for adverse outcomes with excessive heart rates during exercise, and rather, may indicate a trend towards mortality benefit.HRViS Table 1
Effectiveness of AI-enhanced colonoscopy: A case-control study using real world evidence in a young screening age population
AlAhmad, Maryam , Ghoris, Youstina, Thomas, Colleen S. , Atieh, Mutaz I., Abulkas, Heba A., Ahmed, Ishtiaq , Ahmed, Esraa , Ali, Ameirah Bader Abdullah Al, Nagaraju, Darshan, Karajeh, Mohammed , Wallace, M

Mayo Clinic

Saudi Journal of Gastroenterology | February 4, 2026 | Volume: 32 | Issue: 2 | Pages: 131-138

10.4103/sjg.sjg_233_25 | PMID 41637205 Get It

Current State and Needs of Clinical Laboratories in Latin America: A Cross-Country Assessment
Molinelli, Alejandro R. , Palavecino, Elizabeth , Jara-Aguirre, José, Cosby, Kerry, Targowski, Allison, Goldsmith, Barbara, Sierra-Amor, Rosa Isabel, García, Juan D, Algeciras-Schimnich, Alicia, Zabaleta, Eugenio H, Luzzi, Veronica, Colón-Franco, Jessica M , Algeciras-Schimnich, Alicia , Jara-Aguirre, Jose C., Cosby, Kerry, Targowski, Allison, Algeciras‐Schimnich, Alicia , Luzzi, Verónica

Mayo Clinic

The Journal of Applied Laboratory Medicine | February 4, 2026 | Volume: 11 | Issue: 4 | Pages: 927-938

10.1093/jalm/jfag019 | PMID 41808422 Get It

Abstract The Association for Diagnostics & Laboratory Medicine (ADLM) aims to improve health by providing education to laboratory scientists worldwide. Different regions of the world face unique challenges shaped by their national and regional contexts. However, the needs of clinical laboratories worldwide remain largely understudied. To address this gap, we conducted a comprehensive needs assessment survey among laboratory professionals in the Latin American region. The survey was distributed to over 2708 individuals across Latin American countries and yielded 148 responses. Most respondents were from urban areas (74%) and worked in private hospital laboratories (45%), with microbiology (25%) and chemistry (23%) identified as the most common specialties. Key findings include continuing education as the top challenge, identified by 59% of respondents, with a predominant preference for virtual learning formats (83%), though not exclusively; 50% also identified a preference for in-person learning. Other challenges, such as staff shortages, lack of equipment and funding, were selected by 30% to 36% of respondents, whereas regulatory oversight and quality management were less frequently identified as priorities. To contextualize the survey findings, we conducted interviews with laboratory professionals in the region. Common themes included resource and technology constraints, uneven implementation of quality standards, and the need for collaboration between government and professional organizations to bridge gaps in practice. This assessment highlights the need for targeted educational interventions to address the distinct challenges faced by Latin American laboratories. Addressing these gaps in continued education, fostering collaboration, and engaging stakeholders in the region offer a roadmap to strengthening laboratory services and health outcomes.
MIF-CD74 signaling drives immune modulation in medulloblastoma
Draper, Benjamin, You, Zhen , Thompson, Dean, Guo, Xu, Morcavallo, Alaide , Pino, Diego Chillón, Nery, Carlos Lorenzo Gido, Shrestha, Sumana , Himsworth, Courtney , Delaidelli, A., Morlando, Sonia , Wade, Brandon, Gordon, Freya , Sanchez-Corrales, Yara, Hopkins, Bei, Monteiro, Natalie, Locke, Darren, Liu, Miao , Diaz, Jacob Torrejon, Greenslade, Kevin , Costa, Barbara Martins Da , Barker, Karen, Fletcher, Anya, Custódia, Carlos , Roque, Rafael , Jackson, Thomas, Barfoot, Regan, Castellano, Sergi , Hill, Rebecca M. , Saulnier, Olivier , Jacques, Thomas S, Faria, Claudia C , Ayrault, Olivier , Sorensen, Poul H., Anderson, John, Chesler, Louis, Huang, L Frank, Clifford, Steven C. , Castellano, Sergi , Jacques, Thomas S , Donovan, Laura K , Draper, Benjamin , Thompson, Dean , Bowers, Chantelle E , Delaidelli, Alberto , Remeniuk, Bethany , Sánchez-Corrales, Yara E. , Hopkins, Bei, Torrejon-Diaz, Jacob, Barker, Karen T. , Kwok, Colin , Ogunbiyi, Olumide Kayode , Richardson, Stacey , Jackson, Thomas John , Jacques, Thomas S. , Taylor, Michael D. , Anderson, John, Chesler, Louis , Huang, L Frank

Mayo Clinic

Neuro-Oncology | February 3, 2026 | Volume: 28 | Issue: 5 | Pages: 1316-1334

10.1093/neuonc/noag020 | PMID 41652893 Get It

Abstract Background Relapsed medulloblastoma remains a significant therapeutic challenge as it is near universally fatal. The tumor microenvironment of medulloblastoma plays a critical role in tumor progression, influencing tumor growth, immune evasion, and therapeutic resistance. We hypothesized that defining tumor-immune interactions in diagnostic and relapsed medulloblastoma may uncover mechanisms of immune evasion and identify novel therapeutic targets. Methods We analyzed paired primary and recurrent RNA-sequencing data from 140 medulloblastoma patients to profile immune cell composition and validate spatial relationships within the TME. To identify key tumor-immune interactions, we developed a novel algorithm to detect receptor-ligand pairs using single-cell RNA-sequencing data. These interactions were validated across RNA and proteomic datasets. Their functional significance was empirically demonstrated in newly developed immunocompetent models of recurrent medulloblastoma that closely recapitulate the human disease. Results We observed a shift toward a heightened immunosuppressive TME at relapse. Using our algorithm, we identified biologically significant receptor-ligand interactions, most notably MIF-CD74, constitutively expressed at RNA and protein levels across medulloblastoma subgroups, at diagnosis and relapse. Disrupting MIF-CD74 interactions led to significant alterations in the tumor microenvironment, highlighting its functional significance. Conclusions Our multifaceted approach identified key tumor-immune interactions in medulloblastoma. Among these, MIF-CD74 was validated as a targetable interaction, demonstrating the utility of our integrative approach for identifying novel therapeutic targets across multiple tumor types.
Feasibility of Intraoperative Tissue Oxygen Saturation Imaging Using OXEI Technology During Robotic Esophagectomy: A Case Series
Fortich, Susana , Den, Jennifer , Thomas, M., Petrov, Roman , Thomas, Mathew , Thomas, Mathew

Mayo Clinic

Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery | February 3, 2026 | Volume: 21 | Issue: 1 | Pages: 48-55

10.1177/15569845251401204 | PMID 41630619 Get It

Objective: Esophageal cancer is a leading cause of cancer-related mortality, with a 5-year survival rate of 20%. Surgical resection remains the primary treatment for early and locally advanced disease. Anastomotic leak is a major concern, which significantly increases morbidity and mortality. Impaired conduit perfusion and tissue ischemia are key risk factors. This series describes the use of ELUXEO Oxygen Saturation Endoscopic Imaging (OXEI) technology (Fujifilm Healthcare Americas Corp, Lexington, MA, USA) to assess tissue oxygen saturation during esophagectomy. Methods: OXEI was used in 6 cases to evaluate conduit perfusion during esophagectomy procedures. Real-time hemoglobin oxygen saturation imaging identified ischemic areas, with StO 2 levels ranging from 17% in poorly perfused regions to 92% in well-perfused areas. OXEI findings were congruent with indocyanine green fluorescence imaging but avoided dye-related limitations. Results: OXEI technology offered a dye-free alternative that allowed real-time assessment of tissue oxygenation, facilitating accurate perfusion quantification. Its reproducibility without dye administration and limitations of tissue saturation or washout concerns added reliability, especially during long multistage procedures. In addition, OXEI has been shown to be consistent irrespective of distances from the targeted area, providing precise tissue saturation quantification throughout critical steps of esophagectomy. These findings highlight the potential of this technology as a valuable adjunct in esophageal surgery. Conclusions: The experience with ELUXEO technology in esophagectomy is promising. It provides a reliable, dye-free method for real-time perfusion assessment, potentially reducing the incidence of anastomotic leaks, preventing dye-associated complications, and improving surgical outcomes. Further studies are warranted to validate these findings in esophagectomies.
A Call for Education Leadership in Accreditation Reform
Hafferty, Frederic W. , Stern, David Thomas , Lypson, Monica L.

Mayo Clinic

JAMA | February 2, 2026 | Volume: 335 | Issue: 9 | Pages: 753

10.1001/jama.2025.27095 | PMID 41627810 Get It

This Perspective discusses the flaws in the process and methods of institutional external validation in medical education.